Literature DB >> 20494708

Regional liver therapy using oncolytic virus to target hepatic colorectal metastases.

Susanne G Carpenter1, Joshua Carson, Yuman Fong.   

Abstract

The mortality of colorectal carcinoma often results from the progression of metastatic disease, which is predominantly hepatic. Although recent advances in surgical, locoregional, and systemic therapies have yielded modest improvements in survival, treatment of these aggressive lesions is limited to palliation for the vast majority of patients. Oncolytic viral therapy represents a promising novel therapeutic modality that has achieved tumor regression in several preclinical and clinical models. Evidence further suggests that locoregional viral administration may improve viral efficacy while minimizing toxicity. This study will review the theories behind hepatic arterial infusion of oncolytic virus, as well as herpes viral design, preclinical data, and clinical progress in regional liver therapy using oncolytic virus to treat hepatic colorectal carcinoma metastases. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494708      PMCID: PMC3266826          DOI: 10.1053/j.seminoncol.2010.03.001

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  83 in total

1.  The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth.

Authors:  N B Ackerman
Journal:  Surgery       Date:  1974-04       Impact factor: 3.982

2.  Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.

Authors:  Tony R Reid; Scott Freeman; Leonard Post; Frank McCormick; Daniel Y Sze
Journal:  Cancer Gene Ther       Date:  2005-08       Impact factor: 5.987

3.  Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.

Authors:  Sandeep Malhotra; Teresa Kim; Jonathan Zager; Joseph Bennett; Michael Ebright; Michael D'Angelica; Yuman Fong
Journal:  Surgery       Date:  2007-02-14       Impact factor: 3.982

4.  The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.

Authors:  V Papanastassiou; R Rampling; M Fraser; R Petty; D Hadley; J Nicoll; J Harland; R Mabbs; M Brown
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

5.  Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.

Authors:  B M Stiles; P S Adusumilli; A Bhargava; S F Stanziale; T H Kim; M-K Chan; R Huq; R Wong; V W Rusch; Y Fong
Journal:  Cancer Gene Ther       Date:  2006-01-01       Impact factor: 5.987

6.  HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Authors:  S Harrow; V Papanastassiou; J Harland; R Mabbs; R Petty; M Fraser; D Hadley; J Patterson; S M Brown; R Rampling
Journal:  Gene Ther       Date:  2004-11       Impact factor: 5.250

7.  Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice.

Authors:  Y Kulu; J D Dorfman; D Kuruppu; B C Fuchs; J M Goodwin; T Fujii; T Kuroda; M Lanuti; K K Tanabe
Journal:  Cancer Gene Ther       Date:  2008-11-07       Impact factor: 5.987

8.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

Authors:  Ta-Chiang Liu; Taeho Hwang; Byeong-Ho Park; John Bell; David H Kirn
Journal:  Mol Ther       Date:  2008-07-15       Impact factor: 11.454

10.  Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer.

Authors:  Maura Reinblatt; Richard H Pin; Yuman Fong
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

View more
  6 in total

1.  Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.

Authors:  Jun Ren; William R Gwin; Xinna Zhou; Xiaoli Wang; Hongyan Huang; Ni Jiang; Lei Zhou; Pankaj Agarwal; Amy Hobeika; Erika Crosby; Zachary C Hartman; Michael A Morse; Kevin H Eng; H Kim Lyerly
Journal:  Oncoimmunology       Date:  2016-12-07       Impact factor: 8.110

2.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Authors:  Prasad S Adusumilli; Leonid Cherkassky; Jonathan Villena-Vargas; Christos Colovos; Elliot Servais; Jason Plotkin; David R Jones; Michel Sadelain
Journal:  Sci Transl Med       Date:  2014-11-05       Impact factor: 17.956

Review 3.  Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.

Authors:  Hamid R Mirzaei; Analiz Rodriguez; Jennifer Shepphird; Christine E Brown; Behnam Badie
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

4.  Preclinical safety evaluation of hepatic arterial infusion of oncolytic poxvirus.

Authors:  Euna Cho; Eun Jin Ryu; Fen Jiang; Ung Bae Jeon; Mong Cho; Cy Hyun Kim; Miyoung Kim; Nam Deuk Kim; Tae-Ho Hwang
Journal:  Drug Des Devel Ther       Date:  2018-08-08       Impact factor: 4.162

5.  Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma.

Authors:  J Fréderique de Graaf; Marco Huberts; Daphne Groeneveld; Stefan van Nieuwkoop; Casper H J van Eijck; Ron A M Fouchier; Bernadette G van den Hoogen
Journal:  Heliyon       Date:  2022-07-09

Review 6.  Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.

Authors:  Markus Moehler; Katrin Goepfert; Bernd Heinrich; Caroline J Breitbach; Maike Delic; Peter Robert Galle; Jean Rommelaere
Journal:  Front Oncol       Date:  2014-05-01       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.